Julie Mount

Julie Mount

Auto-generated profile, based on publicly available information

Julie Mount

International Medical Affairs, Cardiometabolic Health RWE, Eli Lilly and Company

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
LALaurie S. Anderson
Laurie S. Anderson
HBHeidi G Bell
Heidi G Bell
MGMichael Gilbert
Michael Gilbert
JDJulie E Davidson
Julie E Davidson
CWChristina Winter
Christina Winter
NDNabarun Dasgupta
Nabarun Dasgupta
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.

14 May 2018 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
JDJulie E Davidson
Julie E Davidson
QFQinggong Fu
Qinggong Fu
SRSapna Rao
Sapna Rao
LMLaurence S Magder
Laurence S Magder
MPMichelle Petri
Michelle Petri
Objective Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts, osteoporosis and avascular necrosis that is attributable to cumulative corticosteroid exposure in SLE. Methods Using data from the Hopkins Lupus Cohort, a longitudinal study of lupus activity, organ damage and quality of life in patients with SLE, five matched case–control analyses nested within a prospectively enrolled SLE cohort were performed. Two randomly selected controls were matched to each case using incidence-density sampling from defined risk sets. Attributable risk was calculated for steroid exposure (dose and duration, separately). Cumulative steroid dose was modelled as a four-level categorical variable using clinically relevant thresholds: 0 g (no exposure); >0 and <3.65 g (<10 mg/day for a year); ≥3.65 g and 5 years at 10 mg/day). Results Eligible cases were identified for diabetes (n=42), hypertension (n=79), cataract (n=132), osteoporosis (n=118) and avascular necrosis (n=38). The unadjusted OR for a one-category increase in cumulative steroid exposure ranged from 1.157 (cataract (0.889 to 1.506); p=0.2779) to 2.183 (avascular necrosis (1.162 to 4.103); p=0.0153). After adjusting for confounding variables, a one-category increase in the cumulative steroid dose was significantly associated with risk of cataract (OR (95% CI) 1.855 (1.190 to 2.892); p=0.0064) and osteoporosis (OR (95% CI) 1.604 (1.067 to 2.412); p=0.0232). ORs for avascular necrosis, diabetes and hypertension suggested a moderately increased risk (not significant). Duration of steroid exposure was not associated with any of the outcomes. The proportion of risk attributable to steroid exposure after adjustment for covariates was 0.711 for cataract and 0.540 for osteoporosis. Conclusions Cumulative steroid exposure was associated with an increased risk of cataract and osteoporosis in patients with SLE. Trial registration number NCT01616472.

2 September 2022 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
Simon de LusignanSimon de Lusignan
Simon de Lusignan
AMAndrew McGovern
Andrew McGovern
WHWilliam Hinton
William Hinton
MWMartin Whyte
Martin Whyte
NMNeil Munro
Neil Munro
MFMichael Feher
Michael Feher
Introduction Initiation of injectable therapies in type 2 diabetes (T2D) is often delayed, however the reasons why are not fully understood. Methods A mixed methods study performed in sequential phases. Phase 1: focus groups with people with T2D (injectable naïve [n = 12] and experienced [n = 5]) and healthcare professionals (HCPs; nurses [n = 5] and general practitioners (GPs) [n = 7]) to understand their perceptions of factors affecting initiation of injectables. Phase 2: video-captured GP consultations (n = 18) with actor-portrayed patient scenarios requiring T2D treatment escalation to observe the initiation in the clinical setting. Phase 3: HCP surveys (n = 87) to explore external validity of the themes identified in a larger sample. Results Focus groups identified patients’ barriers to initiation; fear, lack of knowledge and misconceptions about diabetes and treatment aims, concerns regarding lifestyle restrictions and social stigma, and feelings of failure. Facilitators included education, good communication, clinician support and competence. HCP barriers included concerns about weight gain and hypoglycaemia, and limited consultation time. In simulated consultations, GPs performed high-quality consultations and recognised the need for injectable initiation in 9/12 consultations where this was the expert recommended option but did not provide support for initiation themselves. Survey results demonstrated HCPs believe injectable initiation should be performed in primary care, although many practitioners reported inability to do so or difficulty in maintaining skills. Conclusion People with T2D have varied concerns and educational needs regarding injectables. GPs recognise the need to initiate injectables but lack practical skills and time to address patient concerns and provide education. Primary care nurses also report difficulties in maintaining these skills. Primary care HCPs initiating injectables require additional training to provide practical demonstrations, patient education and how to identify and address concerns. These skills should be concentrated in the hands of a small number of primary care providers to ensure they can maintain their skills.

29 April 2024 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
RNRachel S. Newson
Rachel S. Newson
VDVictoria Divino
Victoria Divino
KBKristina S. Boye
Kristina S. Boye
JCJustin Chen
Justin Chen
MDMitch Dekoven
Mitch Dekoven
JMJulie E. Mount
Julie E. Mount
Introduction In people with type 2 diabetes (PwT2D) who also have obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. The objective of this study was to explore the relationship between glycemic control and obesity among PwT2D in Europe and Australia using recent real-world data and applying consistent methodology across countries. Methods Retrospective study utilizing IQVIA electronic medical records (EMR) databases grouped into panels based on specialty of contributing physicians. General practitioner (GP) and endocrinologist/diabetologist (E/D) panels were used in Germany and France, while GP panels were used in Italy, UK and Australia. The Spanish database included all physician specialties. The sample included PwT2D with glycated hemoglobin A1c (HbA1c) and body mass index (BMI) values measured within 90 days of each other between January 2015 and December 2018 (second record termed the ‘index date’). PwT2D had a 1-year baseline period and a recorded HbA1c at the end of the 1-year post-index period. Results The final sample comprised 194,729 PwT2D. At baseline, across countries/panels, 36.8–58.0% were above HbA1c target (HbA1c ≥ 7%) and 39.4–56.7% had obesity (BMI ≥ 30.0 kg/m2). Mean HbA1c ranged from 6.9 to 7.6% and mean BMI ranged from 29.3–31.6 kg/m2. At baseline, a higher proportion of PwT2D with obesity (40.8–64.2%) were above HbA1c target compared to their counterparts without obesity (32.2–52.4%). A higher proportion of patients with obesity at baseline (38.1–60.6%) had post-index HbA1c above target compared to their counterparts without obesity (30.9–56.0%). In logistic regression, patients with obesity had substantially lower odds of post-index HbA1c below target compared to those without obesity in all countries/panels except for France (E/D), Spain and Australia. Conclusions This study presents data on HbA1c and BMI among type 2 diabetes (T2D) populations in Europe and Australia. A notable proportion of PwT2D had obesity and were above HBA1c target. Higher BMI was associated with poorer glycemic control.

1 February 2026 in Current Medical Research and Opinion
Verified
Journal Article
Open access
RSRyo Suzuki
Ryo Suzuki
ALAndrea Leith
Andrea Leith
LHLewis Harrison
Lewis Harrison
YTYoshinori Tanizawa
Yoshinori Tanizawa
MUMoemi Urano
Moemi Urano
JMJulie Mount
Julie Mount
To describe the clinical characteristics, treatment approaches, and disease burden among older people with obesity disease (PwOD) in Japan. Secondary data from the Japanese cohort of the real-world, cross-sectional Adelphi Obesity Disease Specific Programme survey (July-December 2022) were analyzed. Physician's and PwOD's self-reported responses, including quality of life based on the Short Form Health Survey Version 2.0 (SF-36v2.0) and activity impairment from the Work Productivity and Activity Impairment (WPAI) questionnaire, were described by age group (<65 years, ≥65 years, and ≥75 years). Lower SF-36v2.0 scores (<45) and higher percentages in the WPAI questionnaire indicate greater impairment. Physicians (n = 101) provided data for 442 PwOD; 61 PwOD completed self-reported questionnaires. Older PwOD mainly consulted internal medicine physicians (≥65 years [45%] and ≥75 years [70%]). Common weight loss approaches across groups were: diets recommended and supervised by a healthcare provider (HCP)/dietitian/nutritionist/health coach; PwOD's own diet and exercise regime; and prescription obesity management medications. Physicians prioritized non-older PwOD for weight loss surgery or new weight loss drugs. In older PwOD, mean SF-36v2.0 physical component and bodily pain scores, and activity impairment were 34.5 (SD 12.8), 41.5 (SD 7.6), and 33.3% (SD 29.6%), respectively. Major weight loss goals in older PwOD were reducing joint pain and exercising regularly. Older Japanese PwOD faced physical impairments and were generally treated with lifestyle interventions by internal medicine physicians rather than specialists such as endocrinologists/diabetologists. HCPs should recognize obesity disease and obesity-related health disorders and provide appropriate medical care tailored to the specific needs of older PwOD.